Updated

Updated · Livescience.com · Jun 22

Study Links IL-10 Autoantibodies to IBD in 3.5% of Patients as Gene Variant Emerges

Updated

Updated · Livescience.com · Jun 22

Study Links IL-10 Autoantibodies to IBD in 3.5% of Patients as Gene Variant Emerges

Q: Is this newly discovered antibody the true cause of IBD, or is it merely a symptom of the disease itself?

The evidence points to these anti-IL-10 autoantibodies as a disease-driving cause in a specific subgroup of IBD patients, not merely a byproduct of inflammation. The key reason is mechanism. IL-10 is one of the gut’s main anti-inflammatory signals. The newly identified autoantibodies neutralize IL-10, removing that control and allowing inflammatory responses to continue unchecked. In lab tests, the antibodies reduced IL-10 activity, made immune cells less responsive to it, and triggered stronger pro-inflammatory signaling. The case is strengthened by the genetics. Researchers linked the antibodies to HLA-DRB1*01:03, a long-known high-risk variant for severe ulcerative colitis whose biological role had been unclear. That makes the finding more than a simple association: it outlines a plausible chain from genetic susceptibility to harmful autoimmunity to intestinal inflammation. The study also found the antibodies in about 3.5% of IBD patients and essentially none of the controls, suggesting they are not just a common consequence of bowel inflammation. Earlier work in children showed similar antibodies can mimic inherited IL-10 signaling defects, which are already known to cause severe IBD. That said, this is not the cause of all IBD. IBD remains a heterogeneous disease with multiple biological pathways. For this subgroup, the antibodies appear to be a true causal mechanism or major driver. For most patients, other causes are likely involved.

3 articles · Updated · Livescience.com · Jun 22

173 of more than 4,900 IBD patients carried autoantibodies that block the anti-inflammatory protein IL-10, while the antibodies were virtually absent in more than 1,000 people without the disease.
Lab tests showed blood from those patients reduced IL-10 activity and triggered a pro-inflammatory immune response, supporting the idea that a runaway immune mechanism drives disease in this subgroup.
HLA-DRB1*01:03 carriers were far more likely to have the IL-10-blocking autoantibodies, helping explain why the variant has long been tied to severe ulcerative colitis and surgery risk.
The findings point to a distinct IBD subtype that could be identified earlier with genetic or antibody testing and eventually treated with more targeted therapies instead of trial-and-error immune suppression.

Sources

Livescience.com14h ago

New Study Links IL-10 Autoantibodies and HLA-DRB1*01:03 to IBD in 3.5% of Patients

chg.ox.ac.uk14h ago

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease — Centre for Human Genetics

health.yahoo.com14h ago

One underlying cause of inflammatory bowel disease pinpointed in new study

5 Sources

Is this newly discovered antibody the true cause of IBD, or is it merely a symptom of the disease itself?

A genetic key to severe IBD has been found. Can a targeted cure finally replace broad, often ineffective, treatments?

IBD may not be one disease. How many different illnesses have we been treating with a one-size-fits-all approach?

Landmark Discovery: 3.5% of IBD Patients Identified With Anti-IL-10 Autoantibodies and HLA-DRB1*01:03 Variant—A New Path to Personalized Treatment

Overview

In June 2026, a landmark study revealed a new subgroup of inflammatory bowel disease (IBD) patients, making up about 3.5% of cases. These patients have neutralizing autoantibodies that block interleukin-10 (IL-10), a key molecule that normally controls inflammation in the gut. When IL-10 is neutralized, its anti-inflammatory effects are lost, leading to unchecked inflammation and symptoms similar to rare genetic IL-10 defects seen in children. This discovery not only deepens our understanding of IBD but also opens the door to more precise diagnosis and targeted treatments based on the underlying biology of each patient.

...